9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook

Summary by AI BETAClose X

Novonesis reported 9M 2026 organic sales growth of 7% and an adjusted EBITDA margin of 37.9%, and confirmed 2026 guidance of 7–8% organic growth with adjusted EBITDA margin at the higher end of the 37–38% range. Financial strength metrics include NIBD/EBITDA of 1.7x, free cash flow before acquisitions at 17% of sales, and a CAPEX-to-sales ratio of 10.2%. The company completed acquisition of the remaining 77% of MicroBioGen on October 1 and has repurchased EUR 14.8m of a EUR 75m buyback program, supporting growth and capital return plans.

Disclaimer*

UK 100

Latest directors dealings